ALCJ — Crossject SA Share News
0.000.00%
Last trade - 00:00Brief: Crossject Signs R&D Cooperation Agreement With U.S. Department Of Defense
Brief: Crossject H1 Operating Loss Widens To 5.7 Million Euros
Brief: Crossject Announces Commercial Agreement With DESITIN Pharma In Germany
Brief: Crossject FY Net Loss Widens To EUR 10.7 Million
Brief: Crossject Receives 1.1 Million Euros by Bpifrance and Bourgogne-Franche Comte Region
Brief: Crossject Successfully Raises 4 Million Euros In Capital Increase
Brief: Crossject Launches 4 Million Euro Capital Increase
Brief: Crossject Says Production Of Zeneo Will Resume Early 2019
Brief: Significant Reinforcement Of Stake In Crossject Of Historic Shareholder Gemmes Venture
Europe Research Roundup: Ascential, Mediaset, Spire Healthcare Group
Europe Research Roundup: Ashtead Group, John Wood Group, Stora Enso Oyj
Brief: Crossject H1 Operating Loss Widens To EUR 5.3 Million
Brief: Crossject FY Operating Loss Widens To 8.6 Million Euros
Brief: Crossject: Free Allocation Of Warrants (BSA) And Convertible Bond Issue Of 5.25 Million Euros
Brief: Crossject Announces FDA Attributed To Zeneo Midazolam The Oprhan Drug Status
Brief: Crossject H1 net loss widens to 3.4 million euros
Brief: Crossject raises 5 mln euros in capital increase
Brief: Crossject FY operating loss widens to 7.3 million euros
Brief: Crossject gets authorization to conduct study on bioequivalence of Zeneo Midazolam